睿知中国疾病研究地图
候选清单0

即将招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07328802,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed, surgically unresectable locally advanced or metastatic cholangiocarcinoma.

    入选标准第 3 条

  3. No prior systemic therapy; subjects who completed postoperative adjuvant therapy **>6 months ago** are eligible.

    入选标准第 4 条

    Prior anti-angiogenic therapy (e.g., bevacizumab). 8. Active bleeding within 3 months prior to first dose:

    排除标准第 12 条

  4. ECOG PS score 0 or 1.

    入选标准第 7 条

  5. HBsAg-positive AND HBV-DNA > local ULN;

    排除标准第 20 条

  6. At least one measurable lesion per RECIST 1.1 criteria.

    入选标准第 6 条

  7. Other malignancies within 5 years prior to first dose (excluding radically cured basal cell carcinoma, squamous cell carcinoma of skin, or carcinoma in situ).

    排除标准第 1 条

    HIV infection (HIV 1/2 antibody-positive). 20. Untreated active HBV:

    排除标准第 19 条

  8. Surgically sterilized/hysterectomy. 10. All subjects (regardless of gender) at conception risk must use contraception with <1% annual failure rate during treatment and for 120 days after last dose.

    入选标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07328802,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Signed written informed consent prior to any trial-related procedures.
  2. Male or female aged **≥18 years and ≤75 years**.
  3. Histologically or cytologically confirmed, surgically unresectable locally advanced or metastatic cholangiocarcinoma.
  4. No prior systemic therapy; subjects who completed postoperative adjuvant therapy **>6 months ago** are eligible.
  5. Life expectancy >3 months.
  6. At least one measurable lesion per RECIST 1.1 criteria.
  7. ECOG PS score 0 or 1.
  8. Adequate organ function (all laboratory criteria below must be met):
  9. For women of childbearing potential:
  10. Postmenopausal (≥1 year amenorrhea), OR
  11. Surgically sterilized/hysterectomy. 10. All subjects (regardless of gender) at conception risk must use contraception with <1% annual failure rate during treatment and for 120 days after last dose.

排除标准:Exclusion Criteria:

  1. Other malignancies within 5 years prior to first dose (excluding radically cured basal cell carcinoma, squamous cell carcinoma of skin, or carcinoma in situ).
  2. Current participation in interventional clinical trials or receipt of other investigational drugs/devices within 4 weeks before first dose.
  3. Prior therapy with:
  4. Anti-PD-1/PD-L1/PD-L2 agents;
  5. Drugs targeting stimulatory/co-inhibitory T-cell receptors (e.g., CTLA-4, OX-40, CD137).
  6. Systemic administration of antitumor Chinese herbal medicines or immunomodulators (e.g., thymosin, interferon, interleukin) within 2 weeks (except localized use for pleural effusion).
  7. Active autoimmune disease requiring systemic treatment within 2 years (e.g., disease-modifying drugs, corticosteroids ≥10 mg/day prednisone equivalent, immunosuppressants).
  8. Exclusions: Hormone replacement (thyroxine/insulin/physiologic steroids);
  9. Known primary immunodeficiency;
  10. Isolated autoantibody positivity requires investigator confirmation of no autoimmune disease.
  11. Systemic glucocorticoids (excluding topical/inhaled) or immunosuppressive therapy within 4 weeks.Note: Physiologic-dose steroids (≤10 mg/day prednisone equivalent) permitted.
  12. Prior anti-angiogenic therapy (e.g., bevacizumab). 8. Active bleeding within 3 months prior to first dose:
  13. Hemoptysis (≥2.5 mL/fresh blood episode);
  14. Gastrointestinal bleeding. 9. High bleeding risk: Tumor invasion of major vessels or radiologist/investigator-assessed bleeding tendency.
  15. Major surgery within 4 weeks (excluding biopsy). 11. Severe unhealed wounds/ulcers/fractures. 12. Aspirin (>325 mg/day) or platelet-inhibiting NSAIDs for >10 consecutive days within 10 days prior to first dose.
  16. Full-dose anticoagulants/thrombolytics for >10 consecutive days within 10 days prior to first dose.Note: Prophylactic low-dose anticoagulants allowed:
  17. Allogeneic organ transplant (excluding corneas) or hematopoietic stem cell transplant.
  18. Hypersensitivity to sintilimab/bevacizumab or excipients. 18. Inadequate recovery from prior intervention toxicities (i.e., >Grade 1 or not returned to baseline, excluding alopecia/fatigue).
  19. HIV infection (HIV 1/2 antibody-positive). 20. Untreated active HBV:
  20. HBsAg-positive AND HBV-DNA > local ULN;
  21. Exceptions:
  22. Severe uncontrolled cardiac arrhythmias (e.g., complete LBBB, ≥Grade II AV block, VT/AF);
  23. Unstable angina, CHF, NYHA Class ≥II heart failure;
  24. Arterial thromboembolism within 6 months (e.g., MI, stroke, TIA);
  25. Major surgery/unhealed wounds within 4 weeks; biopsy within 7 days (except IV catheterization);
  26. Uncontrolled hypertension (>140/90 mmHg);
  27. Active tuberculosis;
  28. Uncontrolled systemic infection;
  29. Clinical diverticulitis, intra-abdominal abscess, GI obstruction;
  30. Decompensated liver disease/active hepatitis;
  31. Uncontrolled diabetes (fasting glucose >10 mmol/L);
  32. Urine protein ≥++ AND 24-hr urine protein >1.0 g. 25. Psychiatric disorders impairing treatment compliance. 26. Any condition that may:

引自 ClinicalTrials.gov, NCT07328802, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07328802,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07328802